MX2012005103A - Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2 (1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen. - Google Patents

Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2 (1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen.

Info

Publication number
MX2012005103A
MX2012005103A MX2012005103A MX2012005103A MX2012005103A MX 2012005103 A MX2012005103 A MX 2012005103A MX 2012005103 A MX2012005103 A MX 2012005103A MX 2012005103 A MX2012005103 A MX 2012005103A MX 2012005103 A MX2012005103 A MX 2012005103A
Authority
MX
Mexico
Prior art keywords
hexahydrocyclopenta
pyrrol
benzamide
propoxy
cis
Prior art date
Application number
MX2012005103A
Other languages
English (en)
Inventor
Carym Trocme-Thibierge
Aurore Sors
Florence Keime-Guibert
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44351420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012005103(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2012005103A publication Critical patent/MX2012005103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1 H)-il] propoxi} benzamida de fórmula (1) (VER FORMULA). o una de sus sales de adición a un ácido o a una base farmacéuticamente aceptable y un inhibidor de la acetilcolinesterasa.
MX2012005103A 2011-05-02 2012-04-30 Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2 (1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen. MX2012005103A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1101347A FR2974729B1 (fr) 2011-05-02 2011-05-02 Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
MX2012005103A true MX2012005103A (es) 2013-06-05

Family

ID=44351420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005103A MX2012005103A (es) 2011-05-02 2012-04-30 Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2 (1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen.

Country Status (28)

Country Link
US (3) US8940785B2 (es)
EP (1) EP2520296A1 (es)
JP (1) JP2012232978A (es)
KR (2) KR101493757B1 (es)
CN (1) CN102764439A (es)
AP (1) AP3104A (es)
AR (1) AR086146A1 (es)
BR (1) BR102012010244A2 (es)
CA (1) CA2775624A1 (es)
CL (1) CL2012001102A1 (es)
CR (1) CR20120192A (es)
CU (1) CU20120064A7 (es)
EA (1) EA020987B1 (es)
EC (1) ECSP12011862A (es)
FR (1) FR2974729B1 (es)
GE (1) GEP20146076B (es)
MA (1) MA34776B1 (es)
MX (1) MX2012005103A (es)
NI (1) NI201200070A (es)
PE (1) PE20130016A1 (es)
RU (1) RU2013153140A (es)
SG (2) SG185240A1 (es)
SV (1) SV2012004203A (es)
TN (1) TN2012000177A1 (es)
TW (1) TW201247200A (es)
UY (1) UY34050A (es)
WO (1) WO2012150412A1 (es)
ZA (1) ZA201203163B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2976285B1 (fr) * 2011-06-08 2013-05-24 Servier Lab Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent
PL3500253T3 (pl) * 2016-08-18 2020-11-16 Suven Life Sciences Limited Kombinacja odwrotnych agonistów receptora histaminowego-3 z inhibitorami acetylocholinesterazy
MD3500306T2 (ro) * 2016-08-18 2020-10-31 Suven Life Sciences Ltd Combinație triplă de agonist invers al receptorului histaminic 3, inhibitor al acetilcolinesterazei și antagonist al receptorului NMDA
CN108371660B (zh) * 2017-12-14 2020-03-10 五邑大学 一种四氢环戊二烯并吡咯化合物及其衍生物的用途
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
WO2020236159A1 (en) * 2019-05-21 2020-11-26 La Pharma Tech Inc. Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200540155A (en) * 2004-04-28 2005-12-16 Takeda Pharmaceutical Fused quinoline derivative and use thereof
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
TW200845977A (en) * 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
CN101981010A (zh) * 2007-10-10 2011-02-23 武田药品工业株式会社 酰胺化合物
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
FR2937251B1 (fr) * 2008-10-16 2011-03-18 Servier Lab Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
FR2953515B1 (fr) * 2009-12-09 2011-12-23 Servier Lab Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
CL2012001102A1 (es) 2014-06-20
ECSP12011862A (es) 2012-07-31
US20120283244A1 (en) 2012-11-08
CN102764439A (zh) 2012-11-07
EA020987B1 (ru) 2015-03-31
UY34050A (es) 2012-11-30
EA201200527A1 (ru) 2012-12-28
SG2014010904A (en) 2014-05-29
KR20130130238A (ko) 2013-12-02
SV2012004203A (es) 2012-08-23
FR2974729A1 (fr) 2012-11-09
PE20130016A1 (es) 2013-01-26
WO2012150412A1 (fr) 2012-11-08
US20150080379A1 (en) 2015-03-19
CA2775624A1 (fr) 2012-11-02
GEP20146076B (en) 2014-04-10
AP2012006232A0 (en) 2012-04-30
TW201247200A (en) 2012-12-01
NZ599633A (en) 2014-02-28
KR101493757B1 (ko) 2015-02-16
US8940785B2 (en) 2015-01-27
CR20120192A (es) 2012-12-06
AP3104A (en) 2015-01-31
MA34776B1 (fr) 2014-01-02
RU2013153140A (ru) 2015-06-10
CU20120064A7 (es) 2013-12-27
EP2520296A1 (fr) 2012-11-07
NI201200070A (es) 2012-11-09
TN2012000177A1 (fr) 2013-12-12
ZA201203163B (en) 2013-01-30
FR2974729B1 (fr) 2013-04-19
US20150080378A1 (en) 2015-03-19
SG185240A1 (en) 2012-11-29
JP2012232978A (ja) 2012-11-29
BR102012010244A2 (pt) 2013-06-18
KR20140051200A (ko) 2014-04-30
AR086146A1 (es) 2013-11-20

Similar Documents

Publication Publication Date Title
MX2012005103A (es) Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2 (1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen.
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
PH12014502588A1 (en) Catechol o-methyltransferase activity inhibiting compounds
MX367795B (es) Inhibidores de cdk.
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
MY181898A (en) Heterocyclic compounds and uses thereof
MX2014015049A (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos.
MX351471B (es) Derivados de piridinona y pirimidinona como inhibidores del factor xia.
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
IN2015DN00885A (es)
MX2015006223A (es) Composiciones farmaceuticas de inhibidores cetp.
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
PL2532651T3 (pl) Sposób syntezy i postać krystaliczna chlorowodorku 4-{3-[cis-heksahydrocyklopenta[c]pirol-2(1h)-ilo]propoksy} benzamidu i jego wolnej zasady oraz kompozje farmaceutyczne je zawierające
CO6660080A1 (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen
IL222254A0 (en) 7,11-methanocycloocta [b] quinoline derivatives as highly functionalizable acetylcholinesterase inhibitors
GB201004677D0 (en) New salt
AU2012202328A1 (en) New Association Between 4-{3-[cis-Hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-propoxy}Benzamide and an Acetylcholinesterase inhibitor, and Pharmaceutical Compositions Containing It
IN2015DN02600A (es)
MY162757A (en) New Crystalline Forms of 4,4’-[4-Fluoro-7-({4-[4-(3-Fluoro-2-Methylphenyl) Butoxy] Phenyl}Ethynyl)-2-Methyl-1H-Indole-1, 3-Diyl] Dibutanoic Acid
UA105703C2 (uk) 7-бром-5-феніл-3-ариламіно-1,2-дигідро-3н-1,4-бенздіазепін-2-они як анальгетичні агенти
UA67859U (en) 3,4-dimethyl-1-ethylcyclohex-3-ene carboxylic acid
UA92872C2 (ru) Комбинированное антиагрегантное и антиоксидантное лекарственное средство

Legal Events

Date Code Title Description
FA Abandonment or withdrawal